According to report, anti-CXCR4 inhibitors could not only inhibit CXCR4 signaling and mobilize T cells of pancreatic cancer in vivo, but also illustrated higher anti-cancer effect if along with anti-PD-L1 drugs41–43, exhibiting similar promising preclinical results. This evidence concerns the gene CXCR4 and cancer.